DL-alpha tocopheryl acetate

Identification

Brand Names

Mvi Pediatric, Natafort

Generic Name

DL-alpha tocopheryl acetate

DrugBank Accession Number

DB14477

Background

Not Available

Type

Small Molecule

Groups

Approved, Experimental

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for DL-alpha tocopheryl acetate (DB14477)

×

Close

Weight

Average: 472.754
Monoisotopic: 472.391645534

Chemical Formula

C₃₁H₅₂O₃

Synonyms

• all-rac-alfa-tocopheryl acetate
• all-rac-alpha-tocopheryl acetate
• DL-alpha-tocopheryl acetate

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Patient Characteristics	Dose Form
Used in combination to treat	Degenerative retinal disorders	Combination Product in combination with: Pyridoxine (DB00165), Vitamin A (DB00162)	••••••••••••			•••••••
Used in combination to treat	Eye degenerative disorder	Combination Product in combination with: Vitamin A (DB00162), Pyridoxine (DB00165)	••••••••••••			•••••••
Used in combination to treat	Vitamin deficiency	Combination Product in combination with: Vitamin A (DB00162), Pyridoxine (DB00165)	••••••••••••			•••••••
Treatment of	Vitamin e deficiency		••• •••			•••••••

Create Account

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Orlistat	Orlistat can cause a decrease in the absorption of DL-alpha tocopheryl acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.

Food Interactions

No interactions found.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Active Moieties

Name	Kind	UNII	CAS	InChI Key
Vitamin E	prodrug	N9PR3490H9	59-02-9	GVJHHUAWPYXKBD-IEOSBIPESA-N
DL-alpha-Tocopherol	prodrug	7QWA1RIO01	10191-41-0	GVJHHUAWPYXKBD-UHFFFAOYSA-N

Product Images

PreviousNext

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Aquasol E Drops 50unit/ml	Solution / drops	50 unit / mL	Oral	Rhone Poulenc Rorer	1993-12-31	1997-08-13
E Vitamin 200I.U. (synthetic Source) - Cap	Capsule	200 unit / cap	Oral	H.J. Sutton Industries Ltd.	1996-10-25	1998-08-31
E Vitamin 400 I.U. (synthetic Source)-cap	Capsule	400 unit / cap	Oral	H.J. Sutton Industries Ltd.	1996-10-25	1998-08-31
E Vitamin 800I.U.(synthetic Source)-cap	Capsule	800 unit / cap	Oral	H.J. Sutton Industries Ltd.	1996-10-25	1998-08-31
Vitamin E 200iu With Non-med.odorless Garlic	Capsule	200 unit / cap	Oral	Pharmavite	1996-09-06	2003-07-30

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
A/o-26 - Caplet	DL-alpha tocopheryl acetate (100 unit) + Beta carotene (7500 unit) + Calcium (75 mg) + Calcium ascorbate (250 mg) + Copper (1 mg) + Folic acid (.4 mg) + Manganese (2.5 mg) + Racemethionine (50 mg) + Selenium (100 mcg) + Zinc (7.5 mg)	Tablet	Oral	Enviro Tech International Canada	1996-12-19	1999-07-26
Balance Ace - Cap	DL-alpha tocopheryl acetate (200 unit) + Ascorbic acid (250 mg) + Beta carotene (10000 unit) + Cupric oxide (1 mg) + Manganese sulfate (1.5 mg) + Sodium selenate (15 mcg) + Zinc oxide (7.5 mg)	Capsule	Oral	Pharmavite	1996-09-06	2002-07-25
Beta C and E Tab	DL-alpha tocopheryl acetate (200 unit / tab) + Ascorbic acid (250 mg / tab) + Beta carotene (5000 unit / tab)	Tablet	Oral	Ksl Pharmaceuticals	1994-12-31	1997-08-08
Betacept Special Formula Vitamins Cap	DL-alpha tocopheryl acetate (200 unit / cap) + Ascorbic acid (250 mg / cap) + Beta carotene (10000 unit / cap)	Capsule	Oral	Wampole Brands, A Division Of Pangeo Pharma (Canada) Inc.	1993-12-31	2002-07-29
Children's Chew Multi & Min Tab	DL-alpha tocopheryl acetate (15 unit / tab) + Ascorbic acid (30 mg / tab) + Beta carotene (1250 unit / tab) + Biotin (75 mcg / tab) + Calcium carbonate (100 mg / tab) + Choline bitartrate (5 mg / tab) + Copper gluconate (1 mg / tab) + Cyanocobalamin (5 mcg / tab) + Ferrous gluconate (2.5 mg / tab) + Iodine (.075 mg / tab) + Magnesium oxide (25 mg / tab) + Manganese gluconate (.5 mg / tab) + Nicotinamide (10 mg / tab) + Calcium pantothenate (6.25 mg / tab) + Potassium chloride (.5 mg / tab) + Potassium chloride (5 mg / tab) + Pyridoxine hydrochloride (1.25 mg / tab) + Riboflavin (1.25 mg / tab) + Thiamine hydrochloride (1.25 mg / tab) + Vitamin A palmitate (1250 unit / tab) + Vitamin D (200 unit / tab) + Zinc gluconate (1.25 mg / tab)	Tablet	Oral	Natrol, Inc.	1995-12-31	2001-07-30

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Abavite	DL-alpha tocopheryl acetate (13.5 mg/1) + Ascorbic acid (60 mg/1) + Cholecalciferol (0.025 mg/1) + Ferrous sulfate (30 mg/1) + Folic acid (1 mg/1) + Magnesium oxide (25 mg/1) + Mecobalamin (0.5 mg/1) + Niacin (15 mg/1) + Calcium pantothenate (5 mg/1) + Potassium Iodide (0.25 mg/1) + Riboflavin (1.8 mg/1) + Thiamine mononitrate (1.6 mg/1) + Vitamin A palmitate (0.33 mg/1) + Zinc oxide (15 mg/1)	Tablet	Oral	ABACOS HEALTH	2021-03-31	Not applicable
Active FE	DL-alpha tocopheryl acetate (40 [iU]/1) + Ascorbic acid (160 mg/1) + Beta carotene (2100 [iU]/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (1 mg/1) + Cyanocobalamin (30 ug/1) + Folic acid (1250 ug/1) + Iron (75 mg/1) + Magnesium oxide (30 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (4 mg/1) + Thiamine hydrochloride (4 mg/1) + Zinc oxide (20 mg/1)	Tablet	Oral	Gm Pharmaceuticals	2013-11-11	Not applicable
Bal-Care DHA	DL-alpha tocopheryl acetate (3 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (2850 [iU]/1) + Calcium carbonate (219 mg/1) + Cholecalciferol (840 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (.012 mg/1) + Folic acid (1 mg/1) + Iodine (.223 mg/1) + Iron sucrose (1.35 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Omega-3 fatty acids (430 mg/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (4 mg/1) + Sodium feredetate (25.65 mg/1) + Thiamine mononitrate (1.8 mg/1) + Zinc oxide (25 mg/1)	Kit	Oral	Pru Gen Pharmaceuticals	2012-05-01	Not applicable
Bal-Care DHA Essential	DL-alpha tocopheryl acetate (3 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (2850 [iU]/1) + Calcium carbonate (219 mg/1) + Cholecalciferol (840 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (.012 mg/1) + Folic acid (1 mg/1) + Iodine (.223 mg/1) + Iron sucrose (1.35 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Omega-3 fatty acids (374 mg/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (4 mg/1) + Sodium feredetate (25.65 mg/1) + Thiamine mononitrate (1.8 mg/1) + Zinc oxide (25 mg/1)	Kit	Oral	Pru Gen Pharmaceuticals	2012-05-01	Not applicable
Cavan Alpha	DL-alpha tocopheryl acetate (3 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (3000 [iU]/1) + Calcium carbonate (230 mg/1) + Cholecalciferol (800 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + Folic acid (1 mg/1) + Iodine (220 ug/1) + Iron (27 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Omega-3 fatty acids (300 mg/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (4 mg/1) + Thiamine mononitrate (1.8 mg/1) + Zinc oxide (25 mg/1)	Kit	Oral	Seton Pharmaceuticals	2010-07-01	2013-09-30

Categories

Drug Categories

• Vitamin E
• Vitamins
• Vitamins (Fat Soluble)

Classification

Not classified

Affected organisms

Not Available

Chemical Identifiers

UNII

WR1WPI7EW8

CAS number

52225-20-4

InChI Key

ZAKOWWREFLAJOT-UHFFFAOYSA-N

InChI

InChI=1S/C31H52O3/c1-21(2)13-10-14-22(3)15-11-16-23(4)17-12-19-31(9)20-18-28-26(7)29(33-27(8)32)24(5)25(6)30(28)34-31/h21-23H,10-20H2,1-9H3

IUPAC Name

2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydro-2H-1-benzopyran-6-yl acetate

SMILES

CC(C)CCCC(C)CCCC(C)CCCC1(C)CCC2=C(O1)C(C)=C(C)C(OC(C)=O)=C2C

References

General References

Not Available

External Links

Human Metabolome Database

HMDB0034227

ChemSpider

2033

RxNav

317841

ChEBI

182695

ChEMBL

CHEMBL247481

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
2, 3	Completed	Treatment	Substance Abuse / Substance Dependence	1
1	Completed	Other	Anemia	1
1	Withdrawn	Treatment	Burn Injury	1
Not Available	Unknown Status	Treatment	Alcohol Dependency	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Solution / drops	Oral	50 unit / mL
Capsule	Oral
Capsule, coated	Oral	400 IU
Capsule, gelatin coated	Oral
Tablet	Oral
Lozenge	Oral
Liquid	Topical
Cloth	Topical
Liquid	Oral
Injection, solution, concentrate; kit	Intravenous
Injection, powder, lyophilized, for solution	Intravenous
Kit	Intravenous
Solution	Intravenous
Solution	Intravenous	140 mcg
Solution	Oral
Liquid	Intravenous
Capsule, liquid filled; kit; tablet	Oral
Capsule, liquid filled; kit; tablet, film coated	Oral
Capsule, delayed release	Oral
Capsule, gelatin coated; kit; tablet	Oral
Tablet, coated	Oral
Kit	Oral
Capsule, liquid filled	Oral
Tablet, film coated	Oral
Capsule; kit; tablet, coated	Oral
Capsule; kit; tablet, film coated	Oral
Capsule; kit; tablet	Oral
Injection, powder, lyophilized, for solution	Intramuscular; Intravenous
Tablet, chewable	Oral
Capsule	Oral	200 unit / cap
Capsule	Oral	1000 unit / cap
Capsule	Oral	800 unit / cap
Capsule, liquid filled	Oral	1000 IU
Capsule, liquid filled	Oral	1000 mg
Capsule, liquid filled	Oral	400 IU
Capsule	Oral	25 unit / cap
Powder	Oral
Capsule	Oral	400 unit / cap
Capsule	Oral

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
logP	10.42	Chemaxon
pKa (Strongest Basic)	-4.9	Chemaxon
Physiological Charge	0	Chemaxon
Hydrogen Acceptor Count	2	Chemaxon
Hydrogen Donor Count	0	Chemaxon
Polar Surface Area	35.53 Å2	Chemaxon
Rotatable Bond Count	14	Chemaxon
Refractivity	144.53 m3·mol-1	Chemaxon
Polarizability	59.57 Å3	Chemaxon
Number of Rings	2	Chemaxon
Bioavailability	0	Chemaxon
Rule of Five	No	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-00di-3031900000-7f12936e1677f07e3ac1
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-00b9-0000900000-fb1577f3e93415fffde4
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0a4i-9000100000-068498bcc2744d5a75df
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-060r-9216300000-e84db64d7d376799e31c
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0bti-4001900000-203db291537a6a7415d1
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0api-9340100000-dad501303885af430c99
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å2)	Source type	Source
[M-H]-	248.9413355	predicted	DarkChem Lite v0.1.0
[M-H]-	220.67792	predicted	DeepCCS 1.0 (2019)
[M+H]+	248.8047355	predicted	DarkChem Lite v0.1.0
[M+H]+	224.01811	predicted	DeepCCS 1.0 (2019)
[M+Na]+	249.6283355	predicted	DarkChem Lite v0.1.0
[M+Na]+	232.83318	predicted	DeepCCS 1.0 (2019)

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at July 06, 2018 18:56 / Updated at December 01, 2022 11:28